^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Cervical Cancer

    Related cancers:
    1d
    Folic acid inhibits the Wnt/β-catenin pathway by upregulating DKK3 to exert anti-tumor effects in cervical squamous cell carcinoma. (PubMed, Sci Rep)
    FA intervention may serve as an effective strategy to restore DKK3 expression to inhibit the Wnt/β-catenin pathway, thereby exerting antitumor activity. Future cervical cancer prevention and treatment strategies may benefit from dynamic monitoring of DKK3 expression to identify potential beneficiaries and provide targeted FA intervention.
    Journal
    |
    DKK3 (Dickkopf WNT Signaling Pathway Inhibitor 3)
    1d
    Formononetin protects against oxaliplatin-induced peripheral neurotoxicity via Nrf2/HO-1 antioxidant pathway without impairing anticancer efficacy. (PubMed, Neurotoxicology)
    Importantly, unlike the ROS scavenger N-acetylcysteine (NAC), which decreased the anticancer effectiveness of both oxaliplatin and paclitaxel, formononetin maintained their anticancer effects in colorectal cancer HT29 cells and cervical cancer SiHa cells. Taken together, formononetin holds potential as a neuroprotectant to prevent oxaliplatin-induced neurotoxicity without compromising anticancer efficacy.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • HMOX1 (Heme Oxygenase 1)
    |
    paclitaxel • oxaliplatin
    1d
    Non-Coding RNAs and Liquid Biopsies: Emerging Biomarkers for Cervical Cancer. (PubMed, Crit Rev Oncol Hematol)
    Thus, in this comprehensive narrative review, we map the range of candidate ncRNAs reported in the literature and discuss their predictive, diagnostic, prognostic and therapeutic value, including their potential as circulating biomarkers in CC. We also highlight, as a future perspective, how integrated profiling approaches could guide research and support the development of non-invasive strategies for diagnosis, prognostic assessment, and therapy monitoring in CC.
    Review • Journal • Liquid biopsy
    |
    MIR21 (MicroRNA 21) • HOTAIR (HOX Transcript Antisense RNA) • PVT1 (Pvt1 Oncogene) • MIR20A (MicroRNA 20a) • MIR214 (MicroRNA 214) • MIR218 (MicroRNA 218)
    1d
    NCG-Compliance: Compliance to Cervical Cancer Chemoradiation Guidelines: A Multicentric Implementation Audit and Resource Assessment Initiative of National Cancer Grid of India (clinicaltrials.gov)
    P=N/A, N=618, Recruiting, Tata Memorial Hospital
    New trial • Compliance
    1d
    EVICTION: First-in-Human Study of ICT01 in Patients With Advanced Cancer (clinicaltrials.gov)
    P1/2, N=292, Active, not recruiting, ImCheck Therapeutics | Trial completion date: Dec 2025 --> Oct 2026 | Trial primary completion date: Sep 2025 --> Oct 2026
    Trial completion date • Trial primary completion date • Checkpoint inhibition • First-in-human
    |
    Keytruda (pembrolizumab) • ICT01
    1d
    Image-Guided Gynecologic Brachytherapy (clinicaltrials.gov)
    P=N/A, N=54, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date
    1d
    Hyaluronic Acid-based Gel Spacers in Gynecologic Malignancies (clinicaltrials.gov)
    P1, N=14, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center
    New P1 trial
    2d
    Complete remission of recurrent human papillomavirus-associated cervical cancer managed with camrelizumab and nanoparticle albumin-bound paclitaxel as second-line treatment: a case report. (PubMed, Front Immunol)
    The current therapeutic protocols outlined in the National Comprehensive Cancer Network Guidelines 4.2025 edition propose that for second-line or subsequent therapies of cervical carcinoma, prioritized protocols incorporate pembrolizumab administration specifically for patients demonstrating high tumor mutational burden characteristics, positive for programmed cell death ligand 1 expression, or exhibiting microsatellite instability-high/mismatch repair deficiency molecular profiles. Other proposed therapeutic approaches include bevacizumab, paclitaxel, and nanoparticle albumin-bound paclitaxel (nab-paclitaxel)...The patient continues to undergo active clinical surveillance. Our case report illustrates that second-line immunochemotherapy utilizing camrelizumab in combination with nab-paclitaxel exhibits notable efficacy and manageable safety profile.
    Journal • Tumor mutational burden • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    TMB-H • MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • AiRuiKa (camrelizumab) • albumin-bound paclitaxel
    2d
    Co-occurrence of peritoneal mesothelioma and genitourinary cancers: a case series with comparative outcomes. (PubMed, Pleura Peritoneum)
    These findings raise the hypothesis of a potential association between PM and GU malignancy. Shared origins, oncogenesis of similar cell types, environmental exposures or genetic predispositions may contribute and warrant further investigation.
    Journal
    |
    BAP1 (BRCA1 Associated Protein 1)
    2d
    The Women's Screening and Self-Testing Program (PROMETA) Study (clinicaltrials.gov)
    P=N/A, N=8445, Not yet recruiting, Tulane University | Trial completion date: Jan 2031 --> Aug 2028 | Trial primary completion date: Jan 2031 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    Xpert HPV Assay
    2d
    Feasibility of Intravaginal Artesunate as Adjuvant HPV & Cervical Precancer Treatment in Kenya (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Dec 2025 --> Apr 2026 | Trial primary completion date: Nov 2025 --> Apr 2026
    Trial completion date • Trial primary completion date
    2d
    Paclitaxel Therapeutic Drug Monitoring in Cancer Patients (clinicaltrials.gov)
    P=N/A, N=20, Recruiting, Wake Forest University Health Sciences | Trial completion date: Jan 2026 --> Jul 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    paclitaxel